Antinociceptive effect of (-)-epicatechin in inflammatory and neuropathic pain in rats

Behavioural Pharmacology

Volumn 29, Issue , 2018, Pages 270-279

  Quinõnez Bastidas, Geovanna N ^a,b   Pineda Farias, Jorge B ^c   Flores Murrieta, Francisco J ^a,d   Rodriguez Silverio, Juan ^a   Reyes Garcia, Juan G ^a   Godínez Chaparro, Beatriz ^b   Granados Soto, Vinicio ^c   Rocha Gonzalez, Héctor I ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b Division of Biological Sciences and Health   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

( ) epicatechin; ASICs; inflammation; nitric oxide; nociception; opioids; pain; serotonin

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 7 BENZYLIDENENALTREXONE; 7 NITROINDAZOLE; AMILORIDE; CYCLIC GMP; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DICLOFENAC; EPICATECHIN; FAMPRIDINE; GLIBENCLAMIDE; IBERIOTOXIN; KAPPA OPIATE RECEPTOR; METITEPINE; MU OPIATE RECEPTOR; N [2 (DIMETHYLAMINO)ETHYL] N [[4' [[(2 PHENYLETHYL)AMINO]METHYL][1,1' BIPHENYL 4 YL]METHYL]]CYCLOPENTANEPROPANAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; NORBINALTORPHIMINE; POTASSIUM CHANNEL; PREGABALIN; SB 699551; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANALGESIC AGENT; CARRAGEENAN; CATECHIN; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CARRAGEENAN-INDUCED INFLAMMATION; CARRAGEENAN-INDUCED PAW EDEMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; FORMALIN TEST; FORMALIN-INDUCED PAIN; HYPERALGESIA; INFLAMMATORY PAIN; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; RAT; RECEPTOR UPREGULATION; SPINAL NERVE LIGATION INJURY; ANALGESIA; ANIMAL; DRUG EFFECT; FEMALE; METABOLISM; NEURALGIA; PAIN; PAIN MEASUREMENT; PROCEDURES; SPINAL NERVE; WISTAR RAT;

ANALGESICS; ANIMALS; CARRAGEENAN; CATECHIN; CYCLIC GMP; FEMALE; HYPERALGESIA; NALOXONE; NEURALGIA; NOCICEPTION; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN PERCEPTION; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN; SPINAL NERVES;

EID: 85020316727     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000320     Document Type: Article

References (53)

1. Akkol EK, Krmzbekmez H, Küçükboyac N, Gören AC, Yesilada E (2012). Isolation of active constituents from cherry laurel (Laurocerasus officinalis Roem.) leaves through bioassay-guided procedures. J Ethnopharmacol 139:527-532.
2. Al-Hasani R, Bruchas MR (2011). Molecular mechanisms of opioid receptordependent signaling and behavior. Anesthesiology 115:1363-1381.
3. Amarante LH, Duarte ID (2002). The kappa-opioid agonist (± )-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway. Eur J Pharmacol 454:19-23.
4. An SS, Kim YO, Park CH, Lin H, Yoon MH (2014). Antiallodynic effect of intrathecal epigallocatechin-3-gallate due to suppression of reactive oxygen species. Korean J Anesthesiol 67:123-128.
5. Armstead WM (1996). Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Physiol 270:H423-H426.
6. Avila-Rojas SH, Velázquez-Lagunas I, Salinas-Abarca AB, Barragán-Iglesias P, Pineda-Farias JB, Granados-Soto V (2015). Role of spinal 5-HT5A, and 5-HT1A/1B/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats. Brain Res 1622:377-385.
7. Bermúdez-Ocanã DY, Ambriz-Tututi M, Pérez-Severiano F, Granados-Soto V (2006). Pharmacological evidence for the participation of NO-cyclic GMPPKG-K+ channel pathway in the antiallodynic action of resveratrol. Pharmacol Biochem Behav 84:535-542.
8. Carrie GO, Fuchs LC, Winecoff AP, Giulumian AD, White RE (1997). Nitrovasodilator relax mesenteric microvessels by cGMP-induced stimulation of Ca2+-activated K+ channels. Am J Physiol 273:H76-H83.
9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
10. Cunha TM, Roman-Campos D, Lotufo CM, Duarte HL, Souza GR, Verri WA Jr, et al. (2010). Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway. Proc Natl Acad Sci USA 107:4442-4447.
11. Cunha TM, Souza GR, Domingues AC, Carreira EU, Lotufo CM, Funez MI, et al. (2012). Stimulation of peripheral kappa opioid receptors inhibits inflammatory hyperalgesia via activation of the PI3K/AKT/nNOS/NO signaling pathway. Mol Pain 8:10.
12. Dirig DM, Salami A, Rathbun ML, Ozaki GT, Yaksh TL (1997). Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 76:183-191.
13. Duarte IDG, Lorenzetti BB, Ferreira SH (1990). Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol 186:289-293.
14. Duarte IDG, Santos IR, Lorenzetti BB, Ferreira SH (1992). Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxidecGMP pathway. Eur J Pharmacol 217:225-227.
15. Edwards G, Weston AH (1993). The pharmacology of ATP-sensitive K+ channels. Annu Rev Pharmacol Toxicol 33:597-637.
16. Ferreira SH, Nakamura M (1979). II-Prostaglandin hyperalgesia: The peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 18:191-200.
17. Ferreira SH, Duarte ID, Lorenzetti BB (1991). The molecular mechanism of action of peripheral morphine analgesia: Stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 201:121-122.
18. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, et al. (1990). Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 265:11083-11090.
19. Gautam R, Jachak SM (2009). Recent developments in anti-inflammatory natural products. Med Res Rev 29:767-820.
20. Gómez-Guzmán M, Jiménez R, Sánchez M, Romero M, O'Valle F, Lopez-Sepulveda R, et al. (2011). Chronic-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxidedeficient rats. Br J Nutr 106:1337-1348.
21. Granados-Soto V, Flores-Murrieta FJ, Castañeda-Hernández G, López-Munõz FJ (1995). Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac in the rat. Eur J Pharmacol 277:281-284.
22. Granados-Soto V, Rufino MO, Gomes-Lopes LD, Ferreira SH (1997). Evidence for the involvement of nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur J Pharmacol 287:281-284.
23. Granados-Soto V, Arguëlles CF, Rocha-González HI, Godínez-Chaparro B, Flores-Murrieta FJ, Villalón CM (2010). The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. Neuroscience 165:561-568.
24. Hämälaïnen MM, Lovick TA (1997). Involvement of nitric oxide and serotonin in modulation of antinociception and pressor responses evoked by stimulation in the dorsolateral region of the periaqueductal gray matter in the rat. Neuroscience 80:821-827.
25. Hermann A, Gorman AL (1981). Effects of 4-aminopyridine on potassium currents in a molluscan neuron. J Gen Physiol 78:63-86.
26. Huang Y, Chan NW, Lau CW, Yao XQ, Chan FL, Chen ZY (1999). Involvement of endothelium/nitric oxide in vasorelaxation induced by purified green tea-epicatechin. Biochim Biophys Acta 1427:322-328.
27. Kim SH, Chung JM (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
28. Kuang X, Huang Y, Gu HF, Zu XY, Zou WY, Song ZB, et al. (2012). Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats. Eur J Pharmacol 676:51-56.
29. Lopes LS, Marques RB, Pereira SS, Ayres MC, Chaves MH, Cavalheiro AJ, et al. (2010). Antinociceptive effect on mice of the hydroalcoholic fraction and-epicatechin obtained from Combretum leprosum Mart & Eich. Braz J Med Biol Res 43:1184-1192.
30. Lopes Lda S, Marques RB, Fernandes HB, Pereira Sda S, Ayres MC, Chaves MH, et al. (2012). Mechanisms of the antinociceptive action of-epicatechin obtained from the hydroalcoholic fraction of Combretum leprosum Mart & Eic in rodents. J Biomed Sci 19:68.
31. Lorenzetti BB, Ferreira SH (1996). Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. Inflamm Res 45:308-311.
32. Lutfy K, Cowan A (2004). Buprenorphine: A unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402.
33. Millan MJ (1999). The induction of pain: An integrative review. Prog Neurobiol 57:1-164.
34. Moore PK, Wallace P, Gaffen ZA, Hart SL, Babbedge RC (1993). Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 110:219-224.
35. Moreno-Ulloa A, Romero-Perez D, Villarreal F, Ceballos G, Ramirez-Sanchez I (2014). Cell membrane mediated-epicatechin effects on upstream endothelial cell signaling: Evidence for a surface receptor. Bioorg Med Chem Lett 24:2749-2752.
36. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, et al. (1996). cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 93:1480-1485.
37. Munõz-Islas E, Vidal-Cantú GC, Bravo-Hernández M, Cervantes-Durán C, Quinoñez-Bastidas GN, Pineda-Farias JB, et al. (2014). Spinal 5-HT5A receptors mediate 5-HT-induced antinociception in several pain models in rats. Pharmacol Biochem Behav 120:25-32.
38. Nozaki-Taguchi N, Yamamoto T (1998). The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg 86:367-373.
39. Ortiz MI, Torres-López JE, Castañeda-Hernández G, Rosas R, Vidal-Cantú GC, Granados-Soto V (2002). Role of the nitric oxide-cyclic GMP-K+ channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac. Proc West Pharmacol Soc 45:174-177.
40. Pacheco DF, Reis GM, Francischi JN, Castro MS, Perez AC, Duarte ID (2005). delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta1 and delta2 receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sci 78:54-60.
41. Papich MG (2000). Pharmacologic considerations for opiate analgesic and nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract 30:815-837.
42. Quinoñez-Bastidas GN, Cervantes-Durán C, Rocha-González HI, Murbartián J, Granados-Soto V (2013). Analysis of the mechanisms underlying the antinociceptive effect of epicatechin in diabetic rats. Life Sci 93:637-645.
43. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F (2010).-epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension 55:1398-1405.
44. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746-752.
45. Rein D, Lotito S, Holt RR, Keen CL, Schmitz HH, Fraga CG (2000). Epicatechin in human plasma: In vivo determination and effect of chocolate consumption on plasma oxidation status. J Nutr 130 (Suppl):2109S-2114SS.
46. Sánchez-Maldonado C, López-Sánchez P, Anguiano-Robledo L, Leopoldo M, Lacivita E, Terrón JA (2015). GR-127935-sensitive mechanism mediating hypotension in anesthetized rats: Are 5-HT5B receptors involved J Cardiovasc Pharmacol 65:335-341.
47. Steffen Y, Schewe T, Sies H (2007).-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. Biochem Biophys Res Commun 359:828-833.
48. Tang LQ, Wei W, Wang XY (2007). Effects and mechanisms of catechin for adjuvant arthritis in rats. Adv Ther 24:679-690.
49. Tiwari V, Kuhad A, Chopra K (2011). Amelioration of functional, biochemical and molecular deficits by epigallocatechin gallate in experimental model of alcoholic neuropathy. Eur J Pain 15:286-292.
50. Tonussi CR, Ferreira SH (1994). Mechanism of diclofenac analgesia: Direct blockade of inflammatory sensitization. Eur J Pharmacol 251:173-179.
51. Winder CV, Wax J, Been MA (1957). Rapid foot volume measurements on unanesthetized rats, and the question of a phenylbutazone effect on anaphylactoid edema. Arch Int Pharmacodyn Ther 112:174-187.
52. Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, et al. (2001). An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol (1985) 90:2386-2402.
53. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.